Expres2ion Biotech Holding Ab · OMXSTO:EXPRS2
Expres2ion Biotech Holding Ab — Aktiespararna Aktiedagen (September 2025)
23 slides from Expres2ion Biotech Holding Ab's conference presentation, Sep 16, 2025
Slide 1: The deadliest threat to women's health
expreScion BIOTE: Keith Alexander — CFO 16 September 2025 The deadliest threat 4 women's health dese STO: EXPRS2 ExpreSzion Biotech Holding AB
Slide 2: Disclaimer
expreScion BIOTECH Disclaimer This presentation does not constitute or form part of any offer or invitation to purchase or subscribe for, or any offer to underwrite or otherwise acquire, any shares or any other securities in ExpreS2ion Biotech Holding AB (the “Company"). Neither shall the presentati
Slide 3: Breast Cancer is still killing 685,000 women every year
Breast Cancer is still killing 685,000! women expreszion every year — will we let it continue? HER2 expression Annual new breast cancer cases” * 2.3 million women diagnosed each year' — breast : HER? | cancer is the most common cancer worldwide Hmm receptor | 1,400,000 * 685,000 deaths annually! — t
Slide 4: Significant Market Opportunity
Significant Market Opportunity ES2B-C001 is a First-in-Class breast cancer immunotherapy, targeting the entire extracellular domain of HER2 Patient distribution by region and cancer type! 1,000,000 800,000 Expansion to adaitional | patient grouPs 600,000 400,000 — P| ] 200,000 , x = HER2+ BC HER2-lo
Slide 5: Deals for HER2 Emerging Breast Cancer Drugs
expreSeion Deals for HER2 E ing B tC D _ Billion-dollar milestones driven by first and second lines of treatment Key transactions Roche $47B acquisition of + Novartis $16B asset swap + AstraZeneca $7B acquisition of + Merck $4B acquisition of Seattle + Abbvie's $10B+ acquisition of Genetech, includi
Slide 6: |
CONFIDENTIAL | 6
Slide 7: Our Solution: First Immunotherapy to Target All of HER2 with a VLP
Our Solution: First Immunotherapy to Target —_—_expreszion All of HER2 (4 Domains) with a Virus-Like Particle (VLP) \ C HER2 protein (all 4 extra- celular domains) ) 4 Generates a broad immune attack Y (polyclonal antibodies against multiple HER2 epitopes) ( High density display ) QC) (= 50 HER2 mol
Slide 8: Induction of a broad polyclonal immune response
Vehicle Vehicle Vehicle ES2B-C001 ES2B-C001 ES2B-C001 ES2B-C001 ES2B-C001 ES2B-C001 + adjuvant + adjuvant + adjuvant • A further advantage of ES2B-C001 over monoclonal antibodies was the induction of a broad polyclonal immune response, comprising all IgG isotypes, including IgG2a, IgG2b and IgG3, wh
Slide 9: Lung metastases
• 600 500 linemetastases Lung metastases 400 = median) A further advantage of ES2B-C001 over monoclonal antibodies was the induction of a broad polyclonal immune response, comprising • all IgG isotypes, including IgG2a, IgG2b and IgG3, which were previously found to be instrumental in the protection
Slide 10: Tumor volume
• 2.5 Tumor volume (cm3) 2.0 Mean ± SEM 1.5 • A further advantage of ES2B-C001 over monoclonal antibodies was the induction of a broad polyclonal immune response, comprising all IgG isotypes, including IgG2a, IgG2b 1.0 * and IgG3, which were previously found to be instrumental in the protection of t
Slide 11: Phase I Underway - First Patients Dosed, First Immune Response Observed
Phase | Underway - First Patients Dosed, First °*P'®°ss22 Immune Response Observed First patient show significant increase in HER2-specific antibodies after second dose, demonstrating immune response and breaking of HER2 tolerance Open-label, dose escalation Phase | in metastatic HER2+ and HER2-low
Slide 12: From First Signals to Pharma Deal
From First Signals to Pharma Deal Goal: Out-license when Phase II delivers proof — or earlier if signals are strong 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 Phase I: First human data Phase II: Proof of conceptin Breast Cancer Potential Phase Il in Gastric Cancer (in parallel) Regis Phase Il
Slide 13: |
CONFIDENTIAL | 13
Slide 14: We Are a Platform-Based Vaccine Company
expreSceion . BIOTECH We Are a Platform-Based Vaccine Company Multiple shots on goal across cancer and infectious diseases, powered by our ExpreS2 platform Target Pre-clinical DISEASE Project/Target ID Identification Pharmacology cGMP / Tox Phase | Phase II Phase III Collaboration Partner Platform Q
Slide 15: Extensive Immunotherapy Development and Oncology Experience
Extensive Immunotherapy Development and —®*P"* 55422 Oncology Experience Executive Management Fully capable of executing to phase Il POC Bent U. Frandsen CEO 30 years life science management, . business development and finance BALK | | 4 KR] | rcconvoe MSc, Copenhagen Business School experience ” Ph
Slide 16: Cost Discipline & Runway: Lean Operations
Cost Discipline & Runway: Lean Operations SEK ‘000s Operating expense () -10,000 -20,000 4 ~35% YoY -30,000 -40,000 1Q23. 3Q23) 1Q24 3Q24 1925 expreSeion BIOTECH R&D costs (external) : a -5,000 | | | | -10,000 — -20,000 Volatile & dependent upon pipeline activities , 1Q23 2Q23 3Q23 4Q23 1024 2Q24 3Q
Slide 17: Net sales and other operating income
Net sales Other operating income 1Q23 3Q23 1Q24 3Q24 1Q25 1Q23 3Q23 1Q24 3Q24 1Q25
Slide 18: 1Q23 2Q23 3Q23 4Q23 1Q24 2Q24 3Q24 4Q24 1Q25 2Q25
• 88 • 82 77 76 72 69 • 60 58 58 • 49 • 1Q23 2Q23 3Q23 4Q23 1Q24 2Q24 3Q24 4Q24 1Q25 2Q25
Slide 19: |
CONFIDENTIAL | 19
Slide 20: Clinical & Pipeline Catalysts
expreSceion BIOTECH SN Clinical & Pipeline Catalysts ES2B-CO001 + Safety readout expected mid-2026 * Immunogenicity & early efficacy signals (if observable at this early stage) in late 2026 + Nipah Vaccine Lead Candidate Selection: H2 2025 * Oxford Malaria Trials: Phase la data in 2H 2025 & IIb data
Slide 21: TO Warrants — Investor Upside & Company Funding
TO 11 Warrants — Investor Upside & Company = °*?"*s28 Funding * Exercise Period * Subscription period: Sept 18 — Oct 2, 2025 * Exercise price: 14.65 SEK (30% discount from VWAP during Sept 1-12) Sept 18 - Oct ; prichg period |) 2: Subscription |} shore Deliver * Ratio: 40 warrants = 1 new share 9 Ps
Slide 22: Key Risks & How We Mitigate Them
Clinical Trial Risk + Risk: Enrolment pace and early- phase timing uncertainty Mitigation: Expanded sites (Vienna +2 new) and dose-escalation design help address enrolment timing uncertainty; first patients already dosed Key Risks & How We Mitigate Them Partnership Dependence + Risk: External progra
Slide 23: Q&A
expreSceion 5 BIOTECH Q&A EXPRS2 Innovative vaccines for a F investor@ expres2ionbio.com https://investor. expres2ionbio.com
ExpreS2ion Biotech Holding — Aktiespararna Aktiedagen (September 2025) on 6ix